Laura Dawson, MD, FRCPC, professor, Department of Radiation Oncology, University of Toronto, discusses screening and prevention of hepatocellular carcinoma (HCC).
Stay up to date on practice-changing data in community practice.
Navigating the Transformation of AI Cancer Detection and Diagnosis
Stuart J. Schnitt, MD, discussed how AI enhances cancer diagnoses and the need for professional oversight, ethical clarity, and equitable adoption.
Read More
Tailoring Treatments to Better Outcomes in Liver Cancer
In season 4, episode 16 of Targeted Talks, Susanne G. Warner, MD,discusses the importance of tailoring treatments for patients with liver cancer, taking into account the staging of the cancer.
Listen
BOND/CORE-001: uGDB as a Biomarker for Viral Therapy in Bladder Cancer
Colin P.N. Dinney, MD, PhD, discussed updated analyses of the BOND-003 and CORE-001 trials in bladder cancer.
AI-Powered Pathology Tools May Boost Precision Oncology
Stuart J. Schnitt, MD, discussed artificial intelligence enhancements roadblocks, and potential integration for cancer diagnostics with Targeted Oncology.
RP1 and the Future of Oncolytic Therapy in Melanoma
Mohammed Milhem, MBBS discussed the mechanism of action of RP1, the design and preliminary findings of the IGNYTE trial in melanoma.
Higher ctDNA Serves as Early Warning for Melanoma Recurrence Risk
David Polsky, MD, discussed a study showing ctDNA levels before melanoma treatment strongly predict recurrence and its speed, potentially guiding future therapy decisions.